Edition:
United Kingdom

Ipsen SA (IPN.PA)

IPN.PA on Paris Stock Exchange

113.90EUR
4:35pm BST
Change (% chg)

€2.20 (+1.97%)
Prev Close
€111.70
Open
€111.80
Day's High
€114.10
Day's Low
€111.60
Volume
162,553
Avg. Vol
119,151
52-wk High
€155.95
52-wk Low
€98.85

Latest Key Developments (Source: Significant Developments)

Ipsen And Servier Announce Initial Phase 1/2 Clinical Data
Friday, 5 Jul 2019 

July 5 (Reuters) - IPSEN SA ::AND SERVIER ANNOUNCE INITIAL PHASE 1/2 CLINICAL DATA EVALUATING LIPOSOMAL IRINOTECAN (ONIVYDE).APPROXIMATELY THREE QUARTERS OF PATIENTS (71.9%) ACHIEVED DISEASE CONTROL AT WEEK 16, WHILE 34% HAD A RESPONSE (SECONDARY ENDPOINT).71.9% (23/32) OF STUDY PATIENTS IN THE 50/60 PP ACHIEVED DISEASE CONTROL AT 16 WEEKS.TREATMENT EMERGENT ADVERSE EVENTS GRADE 3 OR HIGHER WERE REPORTED BY 20 OF 32 PATIENTS FROM THE 50/60 DOSE POOLED PATIENT ANALYSIS; NO PATIENT REPORTED GRADE 3 OR HIGHER FATIGUE OR PERIPHERAL NEUROPATHY (PRIMARY ENDPOINT).  Full Article

Ipsen Initiates Share Buyback Program To Cover Its New Free Share Allocation Plan
Tuesday, 18 Jun 2019 

June 18 (Reuters) - Ipsen SA ::IPSEN INITIATES A SHARE BUYBACK PROGRAM TO COVER ITS NEW FREE SHARE ALLOCATION PLAN.IT HAS APPOINTED AN INVESTMENT SERVICES PROVIDER TO PURCHASE 150,000 IPSEN SA SHARES, OR ABOUT 0.18% OF THE SHARE CAPITAL.  Full Article

Ipsen, Debiopharm Extend Their Strategic Decapeptyl Partnership For 15 Years
Wednesday, 12 Jun 2019 

June 12 (Reuters) - Ipsen SA ::DEBIOPHARM AND IPSEN EXTEND THEIR STRATEGIC DECAPEPTYL (TRIPTORELIN) PARTNERSHIP FOR ANOTHER 15 YEARS.UNDER THE RENEWED AGREEMENT, BOTH PARTIES WILL CO-DEVELOP NOVEL FORMULATIONS AND EXPLORE ADDITIONAL INDICATIONS FOR OTHER PATIENT POPULATIONS WITH HIGH UNMET NEEDS..  Full Article

Ipsen Reports Double-Digit Sales Growth In Q1 2019
Wednesday, 24 Apr 2019 

April 24 (Reuters) - IPSEN SA ::IPSEN REPORTS STRONG DOUBLE-DIGIT SALES GROWTH IN FIRST QUARTER 2019 AND CONFIRMS FULL YEAR 2019 FINANCIAL TARGETS.Q1 GROUP SALES EUR 597.2 MILLION VERSUS EUR 510.3 MILLION YEAR AGO.FULL YEAR 2019 GUIDANCE CONFIRMED.  Full Article

Clementia Pharma Announces Receipt Of Final Court Approval For Plan Of Arrangement With Ipsen S.A.
Thursday, 11 Apr 2019 

April 11 (Reuters) - Clementia Pharmaceuticals Inc ::CLEMENTIA PHARMACEUTICALS INC. ANNOUNCES RECEIPT OF FINAL COURT APPROVAL FOR PLAN OF ARRANGEMENT WITH IPSEN S.A..CLEMENTIA PHARMACEUTICALS INC - CURRENTLY ANTICIPATED THAT ARRANGEMENT WILL BE COMPLETED ON OR ABOUT APRIL 17, 2019.  Full Article

Ipsen To Acquire Clementia Pharmaceuticals
Monday, 25 Feb 2019 

Feb 25 (Reuters) - IPSEN SA ::IPSEN TO ACQUIRE CLEMENTIA PHARMACEUTICALS TO SIGNIFICANTLY BOOST RARE DISEASE PORTFOLIO.IPSEN TO ACQUIRE ALL OUTSTANDING SHARES OF CLEMENTIA FOR A PURCHASE PRICE OF US$25.00 PER SHARE IN CASH UPFRONT PLUS A CONTINGENT VALUE RIGHT (CVR) OF US$6.00 PER SHARE.  Full Article

Ipsen FY Group Net Sales Rise To 2.22 Billion Euros
Thursday, 14 Feb 2019 

Feb 14 (Reuters) - IPSEN SA ::IPSEN DELIVERS STRONG 2018 RESULTS AND EXPECTS CONTINUED SALES AND PROFIT GROWTH IN 2019.FY GROUP NET SALES REACHED EUR 2,224.8 MILLION, UP 20.1% YEAR-ON-YEAR..CORE OPERATING INCOME REACHED EUR 659.9 MILLION IN 2018, COMPARED TO EUR 503.6 MILLION IN 2017, A GROWTH OF 31.0%.CORE CONSOLIDATED NET PROFIT WAS EUR 491.6 MILLION IN 2018, AN INCREASE OF 35.5% VERSUS EUR 362.7 MILLION IN 2017.SEES 2019 GROUP SALES GROWTH YEAR-ON-YEAR AT CONSTANT CURRENCY GREATER THAN +13.0%.SEES 2019 CORE OPERATING MARGIN AROUND 31.0% OF NET SALES.  Full Article

Ipsen And 3BP Announce First Patient Dosed In IPN01087 Phase I/II Study
Tuesday, 20 Nov 2018 

Nov 20 (Reuters) - IPSEN SA ::IPSEN AND 3BP ANNOUNCE FIRST PATIENT DOSED IN PHASE I/II STUDY FOR FIRST-IN-CLASS RADIONUCLIDE (IPN01087).KEY OBJECTIVE OF PHASE I DOSE-ESCALATION TRIAL (EUDRACT NUMBER 2017-001263-20) IS TO EVALUATE SAFETY AND ACTIVITY.IPN01087 IS A COMPOUND THAT TARGETS CANCER CELLS IN PATIENTS WITH ADVANCED SOLID TUMORS WHICH EXPRESS NEUROTENSIN RECEPTOR SUBTYPE 1 (NTSR1).  Full Article

Ipsen Delivers Strong Sales Growth Of 20.2%1 For The Q3 2018 And Confirms Full Year Guidance
Thursday, 25 Oct 2018 

Oct 25 (Reuters) - Ipsen SA ::IPSEN DELIVERS STRONG SALES GROWTH OF 20.2%1 FOR THE THIRD QUARTER OF 2018 AND CONFIRMS FULL YEAR GUIDANCE.Q3 2018 GROUP SALES GROWTH OF 20.2%.FULL YEAR 2018 GUIDANCE CONFIRMED.FULL YEAR 2018 GUIDANCE CONFIRMED WITH GROUP SALES GROWTH OF GREATER THAN 19.0%1 AND CORE OPERATING MARGIN OF AROUND 29.0% OF SALES.Q3 GROUP SALES EUR 555.9 MILLION VERSUS EUR 470.1 MILLION YEAR AGO.  Full Article

Ipsen Receives Positive CHMP Opinion For Cabometyx
Friday, 21 Sep 2018 

Sept 21 (Reuters) - IPSEN SA ::IPSEN RECEIVES POSITIVE CHMP OPINION FOR CABOMETYX (CABOZANTINIB) FOR THE SECOND-LINE TREATMENT OF PATIENTS WITH HEPATOCELLULAR CARCINOMA (HCC).CHMP POSITIVE OPINION WILL NOW BE REVIEWED BY EUROPEAN COMMISSION (EC).  Full Article

French and Benelux stocks-Factors to watch

May 14 Below are company-related news and stories from French and Benelux media which could have an impact on the region's markets or individual stocks.